Pharma News
Published in:
Volume 5 / Year 2016 / Issue 2
Volume 5 / Year 2016 / Issue 2
The anti-TNF biosimilar CT-P13 had comparable efficacy to infliximab in rheumatoid arthritis over one year
Author(s): GaBI Journal Editor
Page: 96
Page: 96
Submitted: 24 May 2016; Revised: 8 June 2016; Accepted: 10 June 2016; Published online first: 24 June 2016 The introduction of biologicals has revolutionized the treatment of immune-mediated diseases such… Read More »
Switching from the infliximab reference product to CT-P13 in patients with rheumatoid arthritis or ankylosing spondylitis: results of the PLANETAS and PLANETRA extension studies
Author(s): GaBI Journal Editor
Page: 94-5
Page: 94-5
Submitted: 24 May 2016; Revised: 8 June 2016; Accepted: 10 June 2016; Published online first: 24 June 2016 CT-P13, also known by its brand names Remsima or Inflectra, is a… Read More »